# A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

> **NCT03315780** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 12 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dulaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03315780
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-28
- **Primary completion:** 2018-02-28
- **Final completion:** 2018-02-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315780, "A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03315780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*